CD4+ T cells mediate the protective effect of the recombinant asp f3-based anti-aspergillosis vaccine

Infection and Immunity

Volumn 79, Issue 6, 2011, Pages 2257-2266

  Diaz Arevalo, Diana ^a   Bagramyan, Karine ^a   Hong, Teresa B ^a   Ito, James I ^b   Kalkum, Markus ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Division of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTISONE ACETATE; FUNGUS VACCINE; IMMUNOGLOBULIN G; PROTEIN ASP F2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FUNGUS HYPHAE; IMMUNOHISTOCHEMISTRY; LUNG ASPERGILLOSIS; MOUSE; NONHUMAN; PEROXISOME; PHAGOCYTE; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; ANTIBODIES, FUNGAL; ANTIGENS, PLANT; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FUNGAL VACCINES; LYMPHOCYTE ACTIVATION; MICE; RABBITS; VACCINES, SYNTHETIC;

EID: 79959462993     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01311-10     Document Type: Article

References (52)

1. Almawi, W. Y., and O. K. Melemedjian. 2002. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J. Leukoc. Biol. 71:9-15.
2. Almawi, W. Y., and O. K. Melemedjian. 2002. Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids. J. Mol. Endocrinol. 28:69-78.
3. Armstrong-James, D. P., et al. 2009. Impaired interferon-gamma responses, increased interleukin-17 expression, and a tumor necrosis factor-alpha transcriptional program in invasive aspergillosis. J. Infect. Dis. 200:1341-1351.
4. Asif, A. R., et al. 2006. Proteome of conidial surface associated proteins of Aspergillus fumigatus reflecting potential vaccine candidates and allergens. J. Proteome Res. 5:954-962.
5. Baddley, J. W., et al. 2010. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin. Infect. Dis. 50:1559-1567.
6. Beck, O., et al. 2006. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 107:2562-2569.
7. Beesley, J. E. 1993. Immunocyto-chemistry: a practical approach. IRL Press at Oxford University Press, Oxford, United Kingdom.
8. Bonnett, C. R., E. J. Cornish, A. G. Harmsen, and J. B. Burritt. 2006. Early neutrophil recruitment and aggregation in the murine lung inhibit germination of Aspergillus fumigatus conidia. Infect. Immun. 74:6528-6539.
9. Bozza, S., et al. 2004. Dendritic cell-based vaccination against opportunistic fungi. Vaccine 22:857-864.
10. Bozza, S., et al. 2003. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 102:3807-3814.
11. Bromuro, C., et al. 2010. Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 28:2615-2623.
12. Chaturvedi, A. K., A. Kavishwar, G. B. Shiva Keshava, and P. K. Shukla. 2005. Monoclonal immunoglobulin G1 directed against Aspergillus fumigatus cell wall glycoprotein protects against experimental murine aspergillosis. Clin. Diagn. Lab. Immunol. 12:1063-1068.
13. Chaturvedi, A. K., R. Kumar, A. Kumar, and P. K. Shukla. 2009. A monoclonal IgM directed against immunodominant catalase B of cell wall of Aspergillus fumigatus exerts anti-A. fumigatus activities. Mycoses 52:524-533.
14. Choi, J. H., E. Brummer, Y. J. Kang, P. P. Jones, and D. A. Stevens. 2006. Inhibitor kappaB and nuclear factor kappaB in granulocyte-macrophage colony-stimulating factor antagonism of dexamethasone suppression of the macrophage response to Aspergillus fumigatus conidia. J. Infect. Dis. 193: 1023-1028.
15. Clemons, K. V., and D. A. Stevens. 2005. The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. Med. Mycol. 43(Suppl. 1):S101-S110.
16. Cordonnier, C., et al. 2006. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin. Infect. Dis. 42:955-963.
17. Denikus, N., et al. 2005. Fungal antigens expressed during invasive aspergillosis. Infect. Immun. 73:4704-4713.
18. Garlanda, C., et al. 2002. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420:182-186.
19. Hebart, H., et al. 2002. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 100:4521-4528.
20. Hemmann, S., C. Ismail, K. Blaser, G. Menz, and R. Crameri. 1998. Skintest reactivity and isotype-specific immune responses to recombinant Asp f 3, a major allergen of Aspergillus fumigatus. Clin. Exp. Allergy 28:860-867.
21. Hohl, T. M., and M. Feldmesser. 2007. Aspergillus fumigatus: principles of pathogenesis and host defense. Eukaryot. Cell 6:1953-1963.
22. Ibrahim-Granet, O., et al. 2010. In vivo bioluminescence imaging and histopathopathologic analysis reveal distinct roles for resident and recruited immune effector cells in defense against invasive aspergillosis. BMC Microbiol. 10:105.
23. Ito, J. I., and J. M. Lyons. 2002. Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J. Infect. Dis. 186: 869-871.
24. Ito, J. I., J. M. Lyons, D. Diaz-Arevalo, T. B. Hong, and M. Kalkum. 2009. Vaccine progress. Med. Mycol. 47(Suppl. 1):S394-S400.
25. Ito, J. I., et al. 2006. Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect. Immun. 74:5075-5084.
26. Kami, M., N. Murashige, T. Fujihara, N. Sakagami, and Y. Tanaka. 2005. The mechanism for low yield of blood culture in invasive aspergillosis; the clinical importance of antigen detection tests revisited. Bone Marrow Transplant. 36:85-86.
27. Kondori, N., L. Edebo, and I. Mattsby-Baltzer. 2008. A novel monoclonal antibody recognizing beta(1-3) glucans in intact cells of Candida and Cryptococcus. APMIS 116:867-876.
28. Kontoyiannis, D. P., et al. 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50:1091-1100.
29. Latge, J. P. 1999. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12:310-350.
30. Latge, J. P. 2001. The pathobiology of Aspergillus fumigatus. Trends Microbiol. 9:382-389.
31. Levitz, S. M., M. E. Selsted, T. Ganz, R. I. Lehrer, and R. D. Diamond. 1986. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J. Infect. Dis. 154:483-489.
32. Marr, K. A., R. A. Carter, M. Boeckh, P. Martin, and L. Corey. 2002. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100:4358-4366.
33. Mehrad, B., R. M. Strieter, and T. J. Standiford. 1999. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J. Immunol. 162:1633-1640.
34. Montagnoli, C., et al. 2003. A role for antibodies in the generation of memory antifungal immunity. Eur. J. Immunol. 33:1193-1204.
35. Mukherjee, S., S. C. Lee, and A. Casadevall. 1995. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63:573-579.
36. Orsborn, K. I., et al. 2006. Protein expression profiling of Coccidioides posadasii by two-dimensional differential in-gel electrophoresis and evaluation of a newly recognized peroxisomal matrix protein as a recombinant vaccine candidate. Infect. Immun. 74:1865-1872.
37. Ovechkina, Y. Y., R. K. Pettit, Z. A. Cichacz, G. R. Pettit, and B. R. Oakley. 1999. Unusual antimicrotubule activity of the antifungal agent spongistatin 1. Antimicrob. Agents Chemother. 43:1993-1999.
38. Philippe, B., et al. 2003. Killing of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates. Infect. Immun. 71: 3034-3042.
39. Pietrella, D., et al. 2010. A beta-glucan-conjugate vaccine and anti-betaglucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine 28:1717-1725.
40. Ramachandran, H., et al. 2002. IgE binding conformational epitopes of Asp f 3, a major allergen of Aspergillus fumigatus. Clin. Immunol. 103:324-333.
41. Roilides, E., A. Dimitriadou-Georgiadou, T. Sein, I. Kadiltsoglou, and T. J. Walsh. 1998. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect. Immun. 66:5999-6003.
42. Roilides, E., et al. 1997. IL-10 exerts suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J. Immunol. 158:322-329.
43. Roilides, E., K. Uhlig, D. Venzon, P. A. Pizzo, and T. J. Walsh. 1993. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect. Immun. 61: 4870-4877.
44. Schaffner, T., H. U. Keller, M. W. Hess, and H. Cottier. 1982. Macrophage functions in antimicrobial defense. Klin Wochenschr. 60:720-726.
45. Shultz, D. B., M. R. Rani, J. D. Fuller, R. M. Ransohoff, and G. R. Stark. 2009. Roles of IKK-beta, IRF1, and p65 in the activation of chemokine genes by interferon-gamma. J. Interferon Cytokine Res. 29:817-824.
46. Stevens, D. A. 2004. Vaccinate against aspergillosis! A call to arms of the immune system. Clin. Infect. Dis. 38:1131-1136.
47. Stevens, D. A., K. V. Clemons, and M. Liu. 2011. Developing a vaccine against aspergillosis. Med. Mycol. 49(Suppl. 1):S170-S176.
48. Torosantucci, A., et al. 2005. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202:597-606.
49. Torosantucci, A., et al. 2009. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One 4:e5392.
50. Tramsen, L., et al. 2009. Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. Bone Marrow Transplant. 43:13-19.
51. Upton, A., K. A. Kirby, P. Carpenter, M. Boeckh, and K. A. Marr. 2007. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin. Infect. Dis. 44:531-540.
52. Yi, T., et al. 2008. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 112:2101-2110.